New search | Conferencedetail
Print view
 
 

2nd Biosimilar Market Access and Commercialization Strategies Summit

evvnt Platform / evvnt
Conference themes
The FDA's approval of the first wave of biosimilars in 2015 cleared the way for manufacturers to make lower-cost versions of expensive biologic drugs, saving patients money and improving access to vital medications. There is a significant market opportunity ahead for biosimilar developers if they can figure out a strategic plan to enhance the commercialization of the biosimilar.
Professional congress organizer (PCO)
ExL Events
Notes
Speakers: Jay Brown, Sr. Director Outpatient Pharmacy Services, NOVANT HEALTH, INC, Niraj Chhaya, Risk Management, Biosimilars, BOEHRINGER INGELHEIM LIMITED, Mona Chitre, Vice President of Pharmacy, EXCELLUS BLUECROSS BLUESHIELD & more.
 

Enquiries and Registration:

https://go.evvnt.com/228702-1?pid=4832
Ms. Taryn O'Donnell
 
Categories
Pharmacology and Toxicology
Languages
English
Congress fees
USD 2.295,00
(Conference Only - Early Bird Pricing before August 3, 2018: USD 1895.0, Conference Only - Standard Pricing after August 3, 2018: USD 2095.0, Conference Only - Onsite Pricing: USD 2295.0)
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

European Public Health Association (EUPHA)Swiss Tropical and Public Health InstituteÖsterreichisches Rotes KreuznewTreeAMREF - African Medical and Research FoundationHelix - Forschung & Beratung WienEuropean Health Forum GasteinCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio Sanitario

Facebook

Give us your professional opinion

Start survey

Start survey